Literature DB >> 18616527

Reactive oxygen species-mediated cyclin D1 degradation mediates tumor growth retardation in hypoxia, independently of p21cip1 and hypoxia-inducible factor.

Ji-Hong Lim1, Yoon-Mi Lee, Yang-Sook Chun, Jong-Wan Park.   

Abstract

Cell growth arrest is an adaptation process for tumor survival in hypoxic environments. As proliferation is a very complicated and dynamic process, hypoxic growth arrest is not considered to be simply determined by a few molecules. Recently, several research groups have demonstrated that hypoxia-inducible factor (HIF)-1alpha plays a crucial role in hypoxia-induced cell-cycle arrest by inhibiting c-Myc and subsequently inducing p21(cip1) expression. However, we found that hypoxic growth arrest could occur even in p21-null cancer cells, and addressed the p21-independent process of cell-cycle arrest. We show that cyclin D1 was downregulated in various cancer cell lines under hypoxic conditions, which was independent of p21 and HIF-1 and -2alpha expression. It was also found that cyclin D1 was destabilized by the ubiquitin-proteasome system and this degradation process was highly activated by hypoxia. Moreover, antioxidants prevented the hypoxic degradation of cyclin D1 and hydrogen peroxide destabilized cyclin D1 in normoxia. Finally, we demonstrated that ectopic expression of cyclin D1 rescued hypoxic growth arrest in both p21+/+ and p21-/- HCT116 cells. Given the results, we here propose that reactive oxygen species-mediated cyclin D1 degradation contributes to tumor growth retardation in hypoxic environments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18616527     DOI: 10.1111/j.1349-7006.2008.00892.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  A nontranscriptional role for HIF-1α as a direct inhibitor of DNA replication.

Authors:  Maimon E Hubbi; Daniele M Gilkes; Sergio Rey; Carmen C Wong; Weibo Luo; Deok-Ho Kim; Chi V Dang; Andre Levchenko; Gregg L Semenza
Journal:  Sci Signal       Date:  2013-02-12       Impact factor: 8.192

2.  Differential regulation of cyclin D1 expression by protein kinase C α and ϵ signaling in intestinal epithelial cells.

Authors:  Marybeth A Pysz; Fang Hao; A Asli Hizli; Michelle A Lum; Wendy M Swetzig; Adrian R Black; Jennifer D Black
Journal:  J Biol Chem       Date:  2014-06-09       Impact factor: 5.157

3.  Inhibition of hydrogen peroxide signaling by 4-hydroxynonenal due to differential regulation of Akt1 and Akt2 contributes to decreases in cell survival and proliferation in hepatocellular carcinoma cells.

Authors:  Colin T Shearn; Philip Reigan; Dennis R Petersen
Journal:  Free Radic Biol Med       Date:  2012-05-01       Impact factor: 7.376

4.  Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression.

Authors:  Farideh Mehraein-Ghomi; Stacy J Kegel; Dawn R Church; Joseph S Schmidt; Quentin R Reuter; Elizabeth L Saphner; Hirak S Basu; George Wilding
Journal:  Prostate       Date:  2014-03-20       Impact factor: 4.104

5.  TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.

Authors:  E Madan; R Gogna; P Kuppusamy; M Bhatt; U Pati; A A Mahdi
Journal:  Br J Cancer       Date:  2012-07-10       Impact factor: 7.640

6.  Ethanol extracts from the branch of Taxillus yadoriki parasitic to Neolitsea sericea induces cyclin D1 proteasomal degradation through cyclin D1 nuclear export.

Authors:  Su Bin Park; Gwang Hun Park; Ha Na Kim; Hun Min Song; Ho-Jun Son; Ji Ae Park; Hyun-Seok Kim; Jin Boo Jeong
Journal:  BMC Complement Altern Med       Date:  2018-06-20       Impact factor: 3.659

7.  Anti-inflammatory and anti-cancer activity of mulberry (Morus alba L.) root bark.

Authors:  Hyun Ji Eo; Jae Ho Park; Gwang Hun Park; Man Hyo Lee; Jeong Rak Lee; Jin Suk Koo; Jin Boo Jeong
Journal:  BMC Complement Altern Med       Date:  2014-06-25       Impact factor: 3.659

8.  Bradykinin inhibits oxidative stress-induced senescence of endothelial progenitor cells through the B2R/AKT/RB and B2R/EGFR/RB signal pathways.

Authors:  Cong Fu; Bing Li; Yuning Sun; Genshan Ma; Yuyu Yao
Journal:  Oncotarget       Date:  2015-09-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.